{"doi":"10.1007/s10637-023-01410-2","title":"CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial","abstract":"C-X-C motif chemokine receptor 2 (CXCR2) has a role in tumor progression, lineage plasticity, and reduction of immune checkpoint inhibitor efficacy. Preclinical evidence suggests potential benefit of CXCR2 inhibition in multiple solid tumors. In this phase 2 study (NCT03473925), adults with previously treated advanced or metastatic castration-resistant prostate cancer (CRPC), microsatellite-stable colorectal cancer (MSS CRC), or non-small-cell lung cancer (NSCLC) were randomized 1:1 to the CXCR2 antagonist navarixin 30 or 100 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks up to 35 cycles. Primary endpoints were investigator-assessed objective response rate (RECIST v1.1) and safety. Of 105 patients (CRPC, n=40; MSS CRC, n=40; NSCLC, n=25), 3 had a partial response (2 CRPC, 1 MSS CRC) for ORRs of 5%, 2.5%, and 0%, respectively. Median progression-free survival was 1.8-2.4 months without evidence of a dose-response relationship, and the study was closed at a prespecified interim analysis for lack of efficacy. Dose-limiting toxicities occurred in 2/48 patients (4%) receiving navarixin 30 mg and 3/48 (6%) receiving navarixin 100 mg; events included grade 4 neutropenia and grade 3 transaminase elevation, hepatitis, and pneumonitis. Treatment-related adverse events occurred in 70/105 patients (67%) and led to treatment discontinuation in 7/105 (7%). Maximal reductions from baseline in absolute neutrophil count were 44.5%-48.2% (cycle 1) and 37.5%-44.2% (cycle 2) and occurred within 6-12 hours postdose in both groups. Navarixin plus pembrolizumab did not demonstrate sufficient efficacy in this study. Safety and tolerability of the combination were manageable. (Trial registration: ClinicalTrials.gov , NCT03473925).","journal":"Investigational New Drugs","year":2024,"id":417550,"datarank":1.3488377308271138,"base_score":4.219507705176107,"endowment":4.219507705176107,"self_citation_contribution":0.6329261557764161,"citation_network_contribution":0.7159115750506977,"self_endowment_contribution":0.6329261557764161,"citer_contribution":0.7159115750506977,"corpus_percentile":null,"corpus_rank":null,"citation_count":67,"citer_count":67,"citers_with_citation_signal":52,"citers_with_endowment":52,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9539,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT03473925","NCT03177187"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1029416,"name":"Ravit Geva","orcid":"0000-0002-5380-4948","position":1,"is_corresponding":false},{"id":316741,"name":"Hyun Cheol Chung","orcid":"0000-0002-0920-9471","position":2,"is_corresponding":false},{"id":434720,"name":"Charlotte Lemech","orcid":"0000-0002-5399-9431","position":3,"is_corresponding":false},{"id":290807,"name":"Wilson H. Miller","orcid":"0000-0002-7408-1574","position":4,"is_corresponding":false},{"id":659639,"name":"Aaron R. Hansen","orcid":"0000-0002-2363-8707","position":5,"is_corresponding":false},{"id":1203819,"name":"Jong Seok Lee","orcid":"0000-0002-7945-2530","position":6,"is_corresponding":false},{"id":1203820,"name":"Frank Tsai","orcid":"0009-0005-5233-2466","position":7,"is_corresponding":false},{"id":84448,"name":"Benjamin Solomon","orcid":"0000-0003-3059-5730","position":8,"is_corresponding":false},{"id":242798,"name":"Tae Min Kim","orcid":"0000-0001-6145-4426","position":9,"is_corresponding":false},{"id":418655,"name":"Christian Rolfo","orcid":"0000-0002-7860-8417","position":10,"is_corresponding":false},{"id":290380,"name":"Vincent L. Giranda","orcid":null,"position":11,"is_corresponding":false},{"id":1203821,"name":"Yixin Ren","orcid":"0000-0002-8499-4545","position":12,"is_corresponding":false},{"id":1086787,"name":"Fang Liu","orcid":"0000-0003-3028-5927","position":13,"is_corresponding":false},{"id":1203822,"name":"Bhargava Kandala","orcid":"0000-0001-5466-0897","position":14,"is_corresponding":false},{"id":1204700,"name":"Tomoko Freshwater","orcid":null,"position":15,"is_corresponding":false},{"id":58538,"name":"Judy S. Wang","orcid":"0000-0003-4789-4913","position":16,"is_corresponding":false},{"id":260281,"name":"Andrew J. Armstrong","orcid":"0000-0001-7012-1754","position":0,"is_corresponding":true}],"reference_count":34,"raw_metadata":null,"created_at":"2026-07-19T01:56:56.807779Z","pmid":"38324085","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}